JPWO2022056368A5 - - Google Patents

Info

Publication number

JPWO2022056368A5

JPWO2022056368A5 JP2023516491A JP2023516491A JPWO2022056368A5 JP WO2022056368 A5 JPWO2022056368 A5 JP WO2022056368A5 JP 2023516491 A JP2023516491 A JP 2023516491A JP 2023516491 A JP2023516491 A JP 2023516491A JP WO2022056368 A5 JPWO2022056368 A5 JP WO2022056368A5

Authority

JP

Japan

Prior art keywords

crystalline compound

further characterized

compound

diffraction pattern

disorder

Prior art date

2024-09-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 229940126062 Compound A Drugs 0.000 claims description 71
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 71
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 62
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 34
• 201000010099 disease Diseases 0.000 claims description 31
• 208000035475 disorder Diseases 0.000 claims description 31
• 102000015694 estrogen receptors Human genes 0.000 claims description 28
• 108010038795 estrogen receptors Proteins 0.000 claims description 28
• 238000000034 method Methods 0.000 claims description 26
• 230000005855 radiation Effects 0.000 claims description 24
• 239000002904 solvent Substances 0.000 claims description 24
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
• 206010028980 Neoplasm Diseases 0.000 claims description 16
• 238000009825 accumulation Methods 0.000 claims description 16
• 230000002776 aggregation Effects 0.000 claims description 16
• 238000004220 aggregation Methods 0.000 claims description 16
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 12
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 230000004580 weight loss Effects 0.000 claims description 12
• 239000000203 mixture Substances 0.000 claims description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
• 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 10
• 238000004519 manufacturing process Methods 0.000 claims description 9
• TZZDVPMABRWKIZ-XMOGEVODSA-N (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-XMOGEVODSA-N 0.000 claims description 8
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
• 206010006187 Breast cancer Diseases 0.000 claims description 8
• 208000026310 Breast neoplasm Diseases 0.000 claims description 8
• 201000009273 Endometriosis Diseases 0.000 claims description 8
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 8
• 208000035269 cancer or benign tumor Diseases 0.000 claims description 8
• 206010046766 uterine cancer Diseases 0.000 claims description 8
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
• 230000035508 accumulation Effects 0.000 claims description 6
• 239000012296 anti-solvent Substances 0.000 claims description 6
• 230000037011 constitutive activity Effects 0.000 claims description 6
• 230000014509 gene expression Effects 0.000 claims description 6
• 208000013403 hyperactivity Diseases 0.000 claims description 6
• 230000002018 overexpression Effects 0.000 claims description 6
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
• ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 2
• 229940093475 2-ethoxyethanol Drugs 0.000 claims description 2
• 239000002202 Polyethylene glycol Substances 0.000 claims description 2
• 238000001816 cooling Methods 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 229960004756 ethanol Drugs 0.000 claims description 2
• 229940093499 ethyl acetate Drugs 0.000 claims description 2
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
• 229940011051 isopropyl acetate Drugs 0.000 claims description 2
• GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
• 229920001223 polyethylene glycol Polymers 0.000 claims description 2
• 208000024891 symptom Diseases 0.000 claims description 2
• 210000000481 breast Anatomy 0.000 claims 4
• 150000001875 compounds Chemical class 0.000 claims 2